In addition, overexpression of the DLK1-DIO3 region, which harbours a large miRNA cluster and MEG3 (lncRNA) gene promoter, was observed in 50% of patients before treatment with AZA, and this was in conjunction with the diagnosis of AML with myelodysplasia-related changes [79]. This evidence concerns the gene DIO3 and Myelodysplasia.